Truist Financial Maintains RXO Inc(RXO.US) With Buy Rating, Cuts Target Price to $18
A Quick Look at Today's Ratings for RXO Inc(RXO.US), With a Forecast Between $10 to $14
RXO Is Maintained at Neutral by UBS
RXO Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on RXO, Lowers Price Target to $18
RXO Is Maintained at Hold by Stifel
RXO Is Maintained at Equal-Weight by Wells Fargo
RXO Analyst Ratings
Express News | RXO Inc : UBS Cuts Target Price to $14 From $24
Express News | RXO Inc : Stifel Cuts Target Price to $14 From $24
Express News | RXO, Inc : Wells Fargo Cuts Target Price to $15 From $20
RXO Inc (RXO) Q1 2025 Earnings Call Highlights: Navigating Market Challenges With Strategic Growth
Barclays Maintains RXO Inc(RXO.US) With Buy Rating, Cuts Target Price to $18
Morgan Stanley Maintains RXO Inc(RXO.US) With Hold Rating, Cuts Target Price to $23
RXO Inc | 10-Q: Q1 2025 Earnings Report
RXO Inc. Price Target Lowered to $23 From $25 at Morgan Stanley
RXO Inc. Price Target Lowered to $18 From $22 at Barclays
RXO Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
RXO's Q1 Adjusted Loss Unchanged as Revenue Rises
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session